Time Hexarelin Doses — Timing and Protocols Explained

Hexarelin generates the most powerful growth hormone pulse of any synthetic peptide—but only if you time hexarelin doses correctly. A 2004 study published in the Journal of Clinical Endocrinology & Metabolism found that single daily bolus dosing caused complete receptor desensitization within 16 weeks, reducing GH output to baseline despite continued administration. The peptide didn't stop working—the protocol violated the pulsatile nature of endogenous GH secretion. Most hexarelin failures trace back to this mistake: dosing for convenience instead of physiology.

Our team has worked with researchers using hexarelin protocols for years. The difference between a protocol that delivers sustained results and one that burns out in three weeks comes down to understanding receptor kinetics, washout periods, and the specific GH secretagogue receptor subtype hexarelin targets.

How should you time hexarelin doses for optimal GH secretion?

Hexarelin should be administered subcutaneously at 200–300mcg per dose, three times daily, with at least four hours between injections and no food intake within 90 minutes before or 60 minutes after administration. This pulsatile dosing pattern mimics endogenous GH release dynamics and prevents GHSR-1a receptor downregulation, which occurs with single high-dose protocols within 10–14 days.

The critical insight most guides miss: hexarelin's mechanism isn't dose-dependent beyond 200mcg—it's interval-dependent. Growth hormone secretagogue receptor 1a (GHSR-1a) density in the anterior pituitary declines rapidly with sustained agonist exposure. A 300mcg dose administered once daily will produce a massive GH spike on day one and diminishing returns by day ten. Three 200mcg doses spaced across the day maintain receptor sensitivity for 8–12 weeks before cycling off becomes necessary. This article covers the exact receptor dynamics that govern hexarelin timing, the meal-timing constraints that most protocols ignore, and the washout period required to restore receptor density after extended use.

Hexarelin Receptor Kinetics and Desensitization Timelines

Hexarelin binds to growth hormone secretagogue receptor 1a (GHSR-1a) with approximately five times the affinity of GHRP-2 and seven times that of GHRP-6—this potency is the reason it produces the strongest acute GH pulse of any peptide in its class. That same receptor affinity is also why hexarelin desensitizes faster than other secretagogues. GHSR-1a undergoes beta-arrestin-mediated internalization within 20–30 minutes of agonist binding—the receptor is pulled from the cell surface into endosomes where it's either recycled or degraded. Under physiological conditions (brief endogenous ghrelin pulses), receptors recycle to the membrane within 90–120 minutes. Under sustained pharmacological agonism (continuous hexarelin exposure), recycling slows and degradation accelerates.

A 2006 study in Endocrinology demonstrated that continuous GHSR-1a activation reduced surface receptor density by 60% within 48 hours. By day seven, functional receptor availability dropped below 30% of baseline—meaning the same dose that produced a 15-fold GH increase on day one produced only a threefold increase by day seven. This isn't tolerance in the neurological sense—it's receptor internalization at the pituitary level. The peptide is still binding; there are simply fewer receptors available to bind to.

Pulsatile dosing prevents this cascade. When hexarelin is administered with four-hour intervals, receptor internalization occurs but the washout window allows partial membrane recycling before the next dose. Surface receptor density stabilizes at 65–75% of baseline instead of collapsing to 30%—the difference between sustained efficacy and complete tachyphylaxis. Researchers using hexarelin in anti-aging studies have consistently found that three-times-daily protocols maintain GH output for 8–12 weeks, while once-daily protocols lose efficacy by week three.

Meal Timing Constraints and Insulin Interference

Growth hormone and insulin are antagonistic hormones—elevated insulin suppresses GH secretion through direct hypothalamic inhibition and by reducing ghrelin output from gastric X/A-like cells. Hexarelin circumvents ghrelin suppression by acting directly on pituitary GHSR-1a, but it cannot override insulin's central suppression of GHRH (growth hormone-releasing hormone) neurons in the arcuate nucleus. A 2003 study in the American Journal of Physiology found that postprandial insulin elevation reduced hexarelin-stimulated GH output by 40–55% compared to fasted-state administration.

The practical constraint: hexarelin must be administered on an empty stomach—at least 90 minutes after food intake and ideally 60 minutes before the next meal. Protein and carbohydrate both trigger insulin release, but the magnitude and duration differ. A high-carbohydrate meal (50g+) produces an insulin spike lasting 90–120 minutes; a high-protein meal (30g+) produces a moderate but prolonged insulin elevation lasting 150–180 minutes. Fat delays gastric emptying but does not independently suppress GH.

Most effective timing windows: first dose upon waking (12+ hour overnight fast), second dose mid-afternoon (4–5 hours post-lunch), third dose 90 minutes before bed (3+ hours post-dinner). This schedule aligns with natural ultradian GH pulses, which occur approximately every four hours in adults. Evening administration is particularly valuable—nocturnal GH secretion accounts for 60–70% of 24-hour GH output, and hexarelin potentiates this endogenous pulse rather than replacing it.

Water intake does not interfere with hexarelin absorption or GH response. Black coffee, unsweetened tea, and electrolyte solutions without calories are acceptable during the fasting window. Any caloric intake—including MCT oil, collagen, or amino acid supplements marketed as 'fasting-friendly'—will elevate insulin enough to blunt GH output measurably.

Subcutaneous Administration Technique and Absorption Rate

Hexarelin is administered subcutaneously—not intramuscularly—because absorption kinetics from subcutaneous adipose tissue produce the rapid but not instantaneous plasma elevation that optimizes pituitary receptor binding. Intramuscular injection produces faster absorption but a narrower plasma concentration curve, which paradoxically reduces total GH output because the peptide clears before the full secretory cascade completes.

After subcutaneous injection, hexarelin reaches peak plasma concentration (Tmax) in 20–30 minutes, with measurable GH elevation beginning at 10–15 minutes and peaking at 30–45 minutes post-injection. The GH pulse lasts 90–120 minutes before returning to baseline—this duration matches endogenous GH secretion patterns. Subcutaneous administration into abdominal, thigh, or deltoid sites produces equivalent bioavailability; rotating injection sites prevents localized lipohypertrophy but does not affect systemic absorption.

Reconstitution must use bacteriostatic water—not sterile water—because multi-dose vials require antimicrobial preservation. Once reconstituted, hexarelin is stable at 2–8°C (refrigerated) for 28 days; beyond this window, peptide bond hydrolysis reduces potency unpredictably. Lyophilized (powder) hexarelin is stable at room temperature for weeks but should be stored at −20°C for long-term preservation. Any temperature excursion above 25°C for more than 48 hours risks peptide degradation.

Dosing accuracy matters: a 200mcg target dose administered from a vial reconstituted with 2mL bacteriostatic water requires drawing 0.2mL (20 units on an insulin syringe). Over-dilution (e.g., 5mL bacteriostatic water) doesn't reduce potency but increases injection volume unnecessarily. Under-dilution (e.g., 1mL) concentrates the peptide but increases the risk of dosing errors because the margin for measurement error narrows.

Comparison Table: Hexarelin Dosing Protocols

Key Takeaways

• Hexarelin must be dosed three times daily at 200–300mcg per injection with at least four-hour intervals to prevent GHSR-1a receptor desensitization, which occurs within 10–16 days under single-dose protocols.
• Insulin suppresses hexarelin-induced GH secretion by 40–55%, requiring administration at least 90 minutes after food intake and 60 minutes before the next meal.
• Subcutaneous injection into abdominal, thigh, or deltoid sites produces peak plasma concentration in 20–30 minutes, with measurable GH elevation beginning at 10–15 minutes and lasting 90–120 minutes.
• Once reconstituted with bacteriostatic water, hexarelin remains stable for 28 days at 2–8°C—storage beyond this window or any temperature excursion above 8°C risks irreversible peptide degradation.
• Hexarelin protocols should not exceed 12 weeks of continuous use; a 4–8 week washout period allows GHSR-1a receptor density to return to baseline before restarting.

What If: Hexarelin Timing Scenarios

What If I Miss a Scheduled Dose by Two Hours?

Administer the missed dose as soon as you remember, then resume your normal schedule for the next dose—do not double-dose to compensate. If more than four hours have passed since the scheduled time and your next dose is due within two hours, skip the missed dose entirely and continue with the next scheduled injection. Doubling doses to 'catch up' increases the risk of acute receptor saturation without improving cumulative GH output—the pituitary releases GH in discrete pulses, not continuous elevation, so oversaturating receptors at a single timepoint offers no advantage and accelerates desensitization.

What If I Eat a Meal Within 60 Minutes of Dosing?

The GH response will be blunted by 30–50% depending on macronutrient composition—carbohydrate-heavy meals suppress GH more than protein or fat. You will not 'waste' the dose entirely, but the output will be measurably lower than fasted-state administration. If this occurs occasionally (once per week or less), the impact on overall protocol efficacy is minimal. If it occurs frequently, restructure your meal timing: shift the hexarelin dose earlier or later to maintain the 90-minute pre-meal window.

What If I Experience Persistent Fatigue After Starting Three-Times-Daily Dosing?

Hexarelin-induced GH elevation transiently lowers blood glucose through increased insulin sensitivity and gluconeogenesis suppression—this effect peaks 60–90 minutes post-injection and resolves within two hours. If fatigue persists beyond this window or occurs throughout the day, check fasting blood glucose and consider whether caloric intake is sufficient to support the increased metabolic demand. GH is catabolic in the short term (lipolysis, protein turnover) and anabolic long-term (IGF-1-mediated tissue growth)—undereating during active hexarelin protocols compounds the catabolic state and produces chronic fatigue. Our team has seen this pattern repeatedly: researchers increase GH output but fail to adjust macronutrient intake accordingly.

What If I Want to Extend Beyond 12 Weeks Without a Washout Period?

Receptor density will continue declining beyond week 12, and by week 16–20, hexarelin-stimulated GH output typically falls to 30–40% of initial response despite continued dosing. You are not 'breaking' anything permanently, but you are wasting peptide—the same dose produces diminishing returns as surface GHSR-1a availability collapses. A four-week washout allows receptor recycling and membrane re-insertion; an eight-week washout restores receptor density to >90% of baseline. Continuous year-round protocols without cycling off are pharmacologically inefficient and clinically unsupported.

The Unvarnished Truth About Hexarelin Dosing

Here's the honest answer: most hexarelin protocols fail because people dose it like a drug instead of a hormone. GH isn't released continuously—it pulses. Your pituitary doesn't secrete GH steadily across 24 hours; it releases discrete bursts every four hours, triggered by ultradian GHRH secretion from the hypothalamus. Hexarelin mimics that pattern when dosed correctly and destroys receptor sensitivity when dosed incorrectly. A single 500mcg injection before bed might produce a spectacular GH spike on day one—and almost nothing by day fourteen. Three 200mcg doses spaced across the day maintain efficacy for three months. The inconvenience of multiple daily injections is the entire mechanism—it's not a bug, it's the feature. If you're not willing to time hexarelin doses around meals and space them at four-hour intervals, use a different peptide.

Cycling Protocols and Receptor Recovery Periods

Receptor desensitization is reversible—but only with time off. GHSR-1a internalization and degradation occur within days of continuous agonist exposure; receptor resynthesis and membrane reinsertion take weeks. A 2007 study in Molecular Endocrinology found that GHSR-1a mRNA expression (the first step in receptor production) returned to baseline within 10–14 days after stopping agonist administration, but functional surface receptor density lagged by an additional 14–21 days. Translation: stopping hexarelin initiates recovery immediately, but full restoration takes four to six weeks.

Standard cycling protocol: 8–12 weeks on, 4–8 weeks off. The 'on' phase should not exceed 12 weeks regardless of subjective response, because receptor density declines measurably beyond this point even under optimal pulsatile dosing. The 'off' phase should be at least four weeks to allow partial recovery, ideally six to eight weeks for complete restoration. Extending the off-phase beyond eight weeks offers no additional receptor benefit—you're simply delaying the next cycle without improving outcomes.

During the washout period, endogenous GH secretion returns to baseline within 48–72 hours after the final hexarelin dose. Some users report subjective fatigue or reduced recovery during the first week off—this is expected as exogenous GH stimulation ceases and the body readjusts to physiological pulsatility. IGF-1 levels (the downstream marker of GH action) decline more slowly, with a half-life of approximately 12–16 hours; serum IGF-1 returns to pre-protocol baseline within 5–7 days.

Alternative peptides during washout: researchers cycling off hexarelin sometimes substitute GHRP-2 or ipamorelin during the off-phase to maintain mild GH stimulation without further GHSR-1a desensitization. This approach is speculative—no published data directly supports it—but the mechanistic rationale is sound. GHRP-2 binds GHSR-1a with lower affinity than hexarelin, and ipamorelin produces a gentler, more sustained GH elevation without the acute receptor saturation that drives internalization. Real Peptides supplies high-purity GHRP-2 and other research-grade peptides with exact amino-acid sequencing for researchers exploring multi-peptide protocols.

Hexarelin remains the most powerful synthetic GH secretagogue available—but only when dosed with respect for receptor kinetics. Timing matters more than dose size. Pulsatility matters more than convenience. If you structure your protocol around the biology instead of your schedule, hexarelin will deliver sustained results for months. Ignore the timing and you'll wonder why the same peptide that produced dramatic results in week one stopped working by week three.